The PR basically from a few days previous was also clearly intended to stop rumors. That she addressed a rumor that was loudly being suggested not just for ASCO, but for the ASM seems to be consistent with the care they are taking to be clear that no one knows. It does not suggest a Reg FD violation that involved an insider. That’s another rumor.
First it was ASM, she released a PR addressing that there was a clear process, which squashed the ASM rumor, so the next event became the natural object of rumors, and at the ASM she squashed it.
If there had been a presentation scheduled or placeholder paper filed, they could easily explain again that those were merely placeholders put in place in anticipation. But the reality is, they can’t really SAY anything, so we see it and speculate on these things and the when they do not happen, we know it was a placeholder.
But, as for this new theory of a regulatory violation, I see no basis in your explanation or anyone else’s explanation. Seems like just another rumor.
Market Data 
Markets 
AI
